NASDAQ:ENGN enGene (ENGN) Stock Price, News & Analysis → Warren Buffett's 'mystery stock' (From Stansberry Research) (Ad) Free ENGN Stock Alerts $12.67 -0.31 (-2.39%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$12.21▼$13.0150-Day Range$12.98▼$18.2452-Week Range$6.69▼$43.00Volume6,924 shsAverage Volume54,525 shsMarket Capitalization$552.16 millionP/E RatioN/ADividend YieldN/APrice Target$34.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get enGene alerts: Email Address enGene MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside171.5% Upside$34.40 Price TargetShort InterestHealthy0.27% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.14Based on 36 Articles This WeekInsider TradingSelling Shares$786,481 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.03) to ($1.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.58 out of 5 starsMedical Sector256th out of 917 stocksHolding & Other Investment Offices Industry1st out of 14 stocks 4.5 Analyst's Opinion Consensus RatingenGene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageenGene has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about enGene's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.27% of the float of enGene has been sold short.Short Interest Ratio / Days to CoverenGene has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in enGene has recently decreased by 68.91%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldenGene does not currently pay a dividend.Dividend GrowthenGene does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENGN. Previous Next 1.0 News and Social Media Coverage News SentimentenGene has a news sentiment score of -0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 36 news articles for enGene this week, compared to 25 articles on an average week.MarketBeat FollowsOnly 1 people have added enGene to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, enGene insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $786,481.00 in company stock.Percentage Held by Insiders13.70% of the stock of enGene is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions64.16% of the stock of enGene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about enGene's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for enGene are expected to decrease in the coming year, from ($1.03) to ($1.22) per share. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry Research41 banks launch ‘crypto dollar’Everyone knows the US financial system is in the middle of a radical change... The White House wants an all-digital dollar. Plus at least 41 major banks (see if your bank is one of them right here).Here's how you capitalize (including #1 crypto to play it). About enGene Stock (NASDAQ:ENGN)enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.Read More ENGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENGN Stock News HeadlinesApril 23, 2024 | insidertrades.comenGene Holdings Inc. (NASDAQ:ENGN) Major Shareholder De Solidarite Des Travai Fonds Sells 4,575 SharesApril 23, 2024 | insidertrades.comDe Solidarite Des Travai Fonds Sells 47,854 Shares of enGene Holdings Inc. (NASDAQ:ENGN) StockMay 20 at 9:30 AM | msn.comThe Highest-Revving Four-Cylinder Engine Ever In A Production CarMay 20 at 12:32 AM | msn.comAir India Express plane engine catches fire, forcing emergency landing at Bangalore airportMay 19 at 7:18 PM | msn.comPlane makes emergency landing on Spokane freeway due to engine failureMay 19 at 7:18 PM | msn.comWiggins firefighter recovering after being trapped beneath engineMay 19 at 2:17 PM | apnews.comWill Power suffers engine hiccup as Chevrolet and Honda struggle ahead of Indy 500 qualifyingMay 19 at 9:16 AM | msn.comGM's LS3 Vs. LS7 Engine: What's The Difference Between Them?May 19 at 4:15 AM | msn.comThe Incredibly Rare Volvo V8 Engine You've Never Heard OfMay 19 at 3:21 AM | americanbankingnews.comenGene (NASDAQ:ENGN) Shares Gap Down to $14.19May 18 at 5:00 PM | msn.comKyle Larson In Danger Of Missing Indianapolis 500 After Engine TroubleMay 18 at 5:00 PM | msn.comEngine issue derails Kyle Larson’s first Indy 500 qualifying runMay 18 at 12:00 PM | msn.comFive fire engines tackle bus blaze on Richmond Road in TwickenhamMay 18 at 1:59 AM | msn.com'Dream Girl' seeks double-engine government in OdishaMay 18 at 1:59 AM | msn.comIs three better than four? Decoding the economics of engine cylindersMay 18 at 1:59 AM | msn.comWhat’s Inside a 2,000-HP Crate Engine?May 18 at 1:59 AM | msn.com5.9-Liter Cummins Engine History and SpecsMay 17 at 8:36 PM | msn.comThe Honda K24 Engine: Four-Piston Powerhouse Was a Killer KingmakerMay 17 at 10:35 AM | msn.comIf You Have a Used Toyota, Checking a Critical Part Might Save Your EngineMay 17 at 3:40 AM | americanbankingnews.comenGene Holdings Inc. (NASDAQ:ENGN) Given Consensus Rating of "Buy" by AnalystsMay 16, 2024 | msn.comGoogle’s AI-powered search engine could be ‘catastrophic’ for news publishers, critics warnMay 16, 2024 | msn.com10 Of The Biggest V8 Engines Ever Built By Ford, RankedMay 16, 2024 | msn.comVideos Show Boeing Jet's Engine Catching Fire During TakeoffMay 16, 2024 | msn.comPlane forced to make emergency landing after engine catches fire mid-flightMay 15, 2024 | msn.com"Unreal Engine 5 offers unprecedented creative freedom" - the art director behind gun fu game SPINE loves Epic's techSee More Headlines Receive ENGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for enGene and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/20/2024Fiscal Year End10/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Holding & other investment offices Sub-IndustryN/A Current SymbolNASDAQ:ENGN Previous SymbolNASDAQ:ENGN CUSIPN/A CIK1980845 Webwww.engene.com Phone302-273-0765FaxN/AEmployees31Year FoundedN/APrice Target and Rating Average Stock Price Target$34.40 High Stock Price Target$40.00 Low Stock Price Target$30.00 Potential Upside/Downside+164.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$30,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-2.39% Debt Debt-to-Equity RatioN/A Current Ratio0.01 Quick Ratio0.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.66) per share Price / Book-19.71Miscellaneous Outstanding Shares43,580,000Free Float37,610,000Market Cap$566.98 million OptionableN/A Beta-0.40 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Jason D. Hanson Esq. (Age 55)J.D., CEO & Director Comp: $656.58kDr. Alex Nichols Ph.D. (Age 38)President & COO Comp: $504.44kDr. James C. Sullivan M.Sc. (Age 45)Ph.D., Chief Scientific Officer Comp: $524.29kDr. Anthony T. Cheung Ph.D. (Age 52)Co-Founder & CTO Comp: $341.75kMr. John C. Brown D.Sc.FRSC, Ph.D., Co-Founder and Member of Scientific Advisory BoardMr. David Ryan Daws (Age 50)CFO & Head of Business Development Mr. Lee G. Giguere (Age 43)Chief Legal Officer & Corporate Secretary Ms. Sharon TanVP of Project Management & Head of Program ManagementDr. Richard P. Bryce MBChB (Age 67)MFPM, MRCGP, Chief Medical Officer Dr. Raj Pruthi M.D.Senior VP of Urologic Oncology & Clinical DevelopmentMore ExecutivesKey CompetitorsArriVent BioPharmaNASDAQ:AVBPSI-BONENASDAQ:SIBNORIC PharmaceuticalsNASDAQ:ORICVarex ImagingNASDAQ:VREXSilence TherapeuticsNASDAQ:SLNView All CompetitorsInsiders & InstitutionsJanus Henderson Group PLCBought 1,000,000 shares on 5/16/2024Ownership: 2.295%Altitude Crest Partners Inc.Bought 120,289 shares on 5/15/2024Ownership: 0.276%De Solidarite Des Travai FondsSold 47,854 sharesTotal: $717,810.00 ($15.00/share)De Solidarite Des Travai FondsSold 4,575 sharesTotal: $68,670.75 ($15.01/share)Fcpm Iii Services B.V.Bought 8,677,951 shares on 3/7/2024Ownership: 37.408%View All Insider TransactionsView All Institutional Transactions ENGN Stock Analysis - Frequently Asked Questions Should I buy or sell enGene stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for enGene in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ENGN shares. View ENGN analyst ratings or view top-rated stocks. What is enGene's stock price target for 2024? 6 brokers have issued 12-month price targets for enGene's stock. Their ENGN share price targets range from $30.00 to $40.00. On average, they anticipate the company's stock price to reach $34.40 in the next twelve months. This suggests a possible upside of 171.5% from the stock's current price. View analysts price targets for ENGN or view top-rated stocks among Wall Street analysts. How have ENGN shares performed in 2024? enGene's stock was trading at $9.23 at the beginning of 2024. Since then, ENGN stock has increased by 37.3% and is now trading at $12.67. View the best growth stocks for 2024 here. Who are enGene's major shareholders? enGene's stock is owned by many different retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (2.29%) and Altitude Crest Partners Inc. (0.28%). View institutional ownership trends. How do I buy shares of enGene? Shares of ENGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ENGN) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDoes this make you sick?Allegiance GoldThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding enGene Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
